SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMCNet:  Derma Sciences to Present at Sidoti Semiannual Micro-Cap Conference on May 9

[May 06, 2014]

Derma Sciences to Present at Sidoti Semiannual Micro-Cap Conference on May 9

PRINCETON, N.J. --(Business Wire)--

Derma Sciences, Inc. (Nasdaq: DSCI), a tissue regeneration company focused on advanced wound care, announced today that Edward J. Quilty, the Company's chairman and chief executive officer, will present a corporate overview and update at the Sidoti & Company Semiannual Micro-Cap Conference on Friday, May 9, 2014 at 10:40 a.m. Eastern time. The conference is being held at the Grand Hyatt New York Hotel in New York City.

Management will be available for one-on-one meetings at the conference. Please contact conference organizers to schedule a meeting.

About Derma Sciences, Inc.

Derma Sciences is a tissue regeneration company focused on advanced wound and burn care. It offers a line of products with patented technologies to help better manage chronic and hard-to-heal wounds, many of wich result from diabetes and poor vascular functioning. The company recently entered the $500 million market for skin substitute products with its licensing of AMNIOEXCEL® and AMNIOMATRIX® in the first quarter of 2014. AMNIOEXCEL was launched to customers in March 2014 and AMNIOMATRIX will be launched in the second quarter. Its MEDIHONEY® product is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown in clinical studies to be effective in a variety of indications. TCC-EZ® is its gold-standard total contact casting system for diabetic foot ulcers. Other novel products introduced into the $14 billion global wound care market include XTRASORB® for better management of wound exudate, and BIOGUARD® for barrier protection against microbes and other contaminants. Its pharmaceutical wound care products include DSC127, which is currently in Phase 3 clinical trials for the healing of diabetic foot ulcers. The drug candidate is also part of a BARDA grant program for the healing/prevention of tissue damage due to ionizing radiation exposure. The patented API peptide used in DSC127 is also in preclinical testing for scar prevention/reduction. The company also offers a full product line of traditional dressings.


For more information please visit www.dermasciences.com.


[ Back To Technology News's Homepage ]

OTHER NEWS PROVIDERS







Technology Marketing Corporation

800 Connecticut Ave, 1st Floor East, Norwalk, CT 06854 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2014 Technology Marketing Corporation. All rights reserved.